[Editorial] Acute myeloid leukaemia at the extremes

The past decade has seen advances for the treatment of acute myeloid leukaemia (AML), but challenges remain for those at the extremes of the disease, particularly for those older than 65 years, and paediatric patients. Therefore, the announcement on Oct 24, 2025, from the US Food and Drug Administration that expanded the approval of revumenib, a menin inhibitor, for the treatment of relapsed or refractory AML with NPM1 mutations in adult and paediatric patients 1 year and older is a welcome one.